Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns

CMS would absorb 340B drug discount program under leaked HHS reorganization proposal

340B, Centers for Medicare and Medicaid Services, HHS, reorganization, Programs – Publication Format, proposal – intent, drug discount program, United States Health Resources and Services Administration, CMS, Policy, Leaked, Changing

New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities

United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964

Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible